 TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 PRNewswire -- Cannabics Pharmaceuticals Inc. OTCQB: CNBX, a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the companys Board, is a world-renowned economist and currently serves also as the companys Head of Advisory Board. 